Sjögren's syndrome is a systemic autoimmune disease characterized by sicca symptoms and extraglandular manifestations. Anemia, leukopenia, thrombocytopenia and lymphoproliferative disorders are well-known extraglandular, hematological complications of Sjögren's syndrome. These hematologic alterations are usually mild and respond well with steroid therapy. We report a case of a 52-year-old female patient who was initially presented with thrombocytopenia. The patient was then diagnosed with primary Sjögren's syndrome and initially treated with steroid. The patient's platelet count was decreased when steroid was tapered. The dose of steroid could be effectively reduced after combined medication with hydroxychloroquine .
Sjögren's syndrome is an inflammatory autoimmune disease characterized by lymphocytic infiltration of the lacrimal and salivary glands. The most common symptoms are keratoconjunctivitis sicca, xerostomia, and secretory gland-related symptoms such as parotid edema.
Among the symptoms found in regions other than the glands, the reported prevalence of cytopenia is as high as 30%. In a study conducted on 380 patients with Sjögren's syndrome, thrombocytopenia was found in 13% of individuals (62 patients), 0.4% of who showed a platelet count of 50,000/㎕ or less. 1 Thrombocytopenia accompanied by an autoimmune disease is caused by autoantibody against the cell membranes, and it responds well to steroids in many cases. However, for those patients whose thrombocytopenia does not respond well to steroids, or in cases where thrombocytopenia recurs after reducing the dose of the administered steroid, combined administration with a high-dose steroid, immunosuppressant, and immunoglobulin is attempted. 2 Here, the authors report a case of a patient who was diagnosed with Sjögren's syndrome during a differential diagnosis of thrombocytopenia and whose thrombocytopenia was addressed using a combined treatment of steroids and hydroxychloroquine, an antimalarial drug. patient's platelet level increased to 74,000/㎕. The prednisolone dosage was gradually decreased after maintaining the hydroxychloroquine therapy at 300 ㎎/day. Fifteen months after the start of the combined administration of hydroxychloroquine, the patient's platelet level was recovered to 106,000/µL without any adverse drug effects or exacerbation of the xerostomia or xeroma. The prednisolone dosage was reduced to 2.5 mg/day and a platelet level of 60,000-100,000/㎕ has been maintained (Fig. 2) .
DISCUSSION
The patient in the present case report was treated with nonsegmented heparin and antiplatelet drug medication due to a myocardial infarction that was diagnosed 4.5 years before her visit to our institution. However, even after the medication was discontinued, the platelet level was not recovered. (NHIRD), showed that the patients had a pulmonary thromboembolism incidence rate that was 3.29 higher than that of the control group, and it was reported that Sjögren's syndrome itself is an independent risk factor. 4 The patient in the present case report had Cytopenia, which is the most common symptom of primary Sjögren's syndrome, has a prevalence rate of 14%-42% as leukocytopenia, about 11% as anemia, and 5%-15% as thrombocytopenia. In the present case, the patient intermittently showed thrombocytopenia in the range of 70,000-90,000/µL in blood tests that were performed about 2 years prior to the patient's diagnosis of Sjögren's syndrome. This suggests that it is important to consider an autoimmune disease as a differential disease during the patient's initial history taking, physical examination, and blood tests when a patient has thrombocytopenia, and it is also essential to verify the symptoms and signs that imply an autoimmune disease in order to make a timely diagnosis.
Although the accurate mechanism has yet to be determined, it is known that immune thrombocyto- B-cell and T-cell receptors. Given that it was recently found that hydroxychloroquine has anticancer, antithrombotic, and antibiotic effects, the scope of hydroxychloroquine application is thus being extended. 9 In addition, since hydroxychloroquine inhibits platelet agglutination and arachidonic acid secretion, and it also suppresses the action of antiphospholipid antibodies, it is used to prevent thromboembolism in patients who are hard to move and antiphospholipid syndrome patients. 9 By administering hydroxychloroquine to the patient in the present case (who has a history of thromboembolism), it may have a dual effect insofar as it not only treats thrombocytopenia, but it also prevents thromboembolism.
In one study, the use of hydroxychloroquine ( 
